Exploiting Inhibitory Siglecs to Combat Food Allergies
Abstract
During this award, we have generated and published important data related to targeting of CD22 on B cells and CD33 on mast cells and basophils to abrogate food allergies. For the CD22 approach, we have demonstrated prevention of IgE production by pre-treating mice with a single injection of Ara h 1, 2, and 3 STALs. Furthermore, we demonstrated that peanut allergen STALs can deplete memory B cells in mice. Finally, we went on to show that the human CD22 ligand can be used to deplete human memory B cells in humanized NSG mice. In the project targeting CD33, we have demonstrated in vivo efficacy in mouse models of anaphylaxis and developed a novel approach by conjugating human CD33 ligand directly to anti-human IgE, without the use of liposomes for scaffolding. This molecule is effective in inducing tolerance in humanized mice. Overall, our results move us closer to translating our STALs platform into human studies by focusing now on the use of humanized mouse models and human CD22 and CD33 ligands in our systems. Finally, our team was awarded an Expansion Award to continue our work on both CD22 and CD33 as targets for Food Allergy. The Expansion Award (W81XWH-21-1-0315) is focused on further developing our findings from the original award by performing experiments on additional humanized mouse models and human basophils and mast cells.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2022
- Accession Number
- AD1179155
Entities
People
- James C. Paulson
- Michael Kulis
Organizations
- University of North Carolina at Chapel Hill